GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Initiator Pharma A/S (OSTO:INIT) » Definitions » EV-to-EBITDA

Initiator Pharma A/S (OSTO:INIT) EV-to-EBITDA : -16.15 (As of Jun. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Initiator Pharma A/S EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Initiator Pharma A/S's enterprise value is kr549.07 Mil. Initiator Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-34.01 Mil. Therefore, Initiator Pharma A/S's EV-to-EBITDA for today is -16.15.

The historical rank and industry rank for Initiator Pharma A/S's EV-to-EBITDA or its related term are showing as below:

OSTO:INIT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.96   Med: 0   Max: 0
Current: -16.15

OSTO:INIT's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.48 vs OSTO:INIT: -16.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-14), Initiator Pharma A/S's stock price is kr10.30. Initiator Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.547. Therefore, Initiator Pharma A/S's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Initiator Pharma A/S EV-to-EBITDA Historical Data

The historical data trend for Initiator Pharma A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Initiator Pharma A/S EV-to-EBITDA Chart

Initiator Pharma A/S Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -13.67 -7.97 -10.27 -4.51 -11.63

Initiator Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.57 -7.61 -8.75 -11.63 -14.16

Competitive Comparison of Initiator Pharma A/S's EV-to-EBITDA

For the Biotechnology subindustry, Initiator Pharma A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Initiator Pharma A/S's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Initiator Pharma A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Initiator Pharma A/S's EV-to-EBITDA falls into.



Initiator Pharma A/S EV-to-EBITDA Calculation

Initiator Pharma A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=549.074/-34.006
=-16.15

Initiator Pharma A/S's current Enterprise Value is kr549.07 Mil.
Initiator Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-34.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Initiator Pharma A/S  (OSTO:INIT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Initiator Pharma A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.30/-0.547
=At Loss

Initiator Pharma A/S's share price for today is kr10.30.
Initiator Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.547.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Initiator Pharma A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Initiator Pharma A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Initiator Pharma A/S (OSTO:INIT) Business Description

Traded in Other Exchanges
N/A
Address
Co/ COBIS, Ole Maaloesvej 3, Copenhagen, DNK, 2200
Initiator Pharma A/S is a clinical Stage Life Science company engaged in the research and development of various drugs targeting medical needs within the central and peripheral nervous system. The company's principal drug candidate is the IPED2015, a type of monoamine reuptake inhibitor (MRI) that has completed preclinical development for the treatment of erectile dysfunction in men. Its MRI drug candidates also include IPDP2015 for the treatment of depression; and IPNP2015 to treat neuropathic pain.

Initiator Pharma A/S (OSTO:INIT) Headlines

No Headlines